Vanguard Group Inc. Sells 176,747 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Vanguard Group Inc. cut its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 2.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,243,262 shares of the medical equipment provider's stock after selling 176,747 shares during the quarter. Vanguard Group Inc. owned 10.42% of Lantheus worth $647,982,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Geode Capital Management LLC raised its position in Lantheus by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider's stock valued at $184,798,000 after buying an additional 32,551 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Lantheus by 47.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider's stock valued at $1,041,000 after purchasing an additional 3,772 shares during the last quarter. Empirical Asset Management LLC bought a new position in shares of Lantheus during the fourth quarter valued at about $323,000. Focus Financial Network Inc. purchased a new position in Lantheus during the fourth quarter worth about $292,000. Finally, Harbor Capital Advisors Inc. grew its position in Lantheus by 12.8% in the 4th quarter. Harbor Capital Advisors Inc. now owns 145,379 shares of the medical equipment provider's stock worth $13,006,000 after purchasing an additional 16,466 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. JMP Securities reissued a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. The Goldman Sachs Group started coverage on Lantheus in a research report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price objective on the stock. B. Riley decreased their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Finally, Truist Financial lifted their target price on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $129.43.

Insider Buying and Selling

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the firm's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the sale, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 64,109 shares of company stock valued at $6,110,806. Company insiders own 2.00% of the company's stock.

Lantheus Stock Performance

NASDAQ:LNTH traded down $6.29 during trading hours on Friday, reaching $90.92. The stock had a trading volume of 1,158,346 shares, compared to its average volume of 944,377. Lantheus Holdings, Inc. has a 12-month low of $58.46 and a 12-month high of $126.89. The stock has a 50 day simple moving average of $93.31 and a 200 day simple moving average of $96.18. The stock has a market cap of $6.23 billion, a P/E ratio of 15.13 and a beta of 0.38.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to analysts' expectations of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. On average, equities analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.